Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifabutin in Mycobacterium Abscessus Lung Disease
NCT07514364Phase 4
Key facts
- Status
- Recruiting
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Countries
- 1
- Sponsor
- National Taiwan University Hospital
- Modality
- Small Molecules
- Drugs
- rifabutin
- Conditions
- Mycobacterium abscessus lung disease
01
Overview
Phase 4, randomised trial of rifabutin in Mycobacterium abscessus lung disease (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Number of patients screened and enrolled at 2 years. Started Jan 2026; status: recruiting.
02
Design
2 arms- Study design
- Randomized
Treatment Group
Standard Rifabutin dose group: Oral administration once daily, combined with standard therapy.
Control Group
Standard therapy: Amikacin, Imipenem, Tigecycline, Linezolid, and Clarithromycin or Azithromycin.
03
Who it enrols
Adults with Mycobacterium abscessus pulmonary disease showing inducible resistance to clarithromycin, clinically stable with active infection on radiography. Excludes pregnant/breastfeeding women and those with rifabutin hypersensitivity.
04
Endpoints
Primary
Number of patients screened and enrolled
Beyond the preview
Go deeper on NCT07514364.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514364.